Pancreatic Cancer Research

ResearcherFudan UniversityActive in the last 2 years

Xiaomeng He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5254-4005; OpenAlex author ID A5029128977. Sources: OpenAlex.

Their work

Papers
8 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers

Papers 8

  1. CircHPCAL1 promotes the progression of pancreatic cancer via the regulation of STEAP2. Co-author DOI 10.1002/ctm2.70501↗
  2. N6-Methylandenosine-related lncRNAs as potential biomarkers for predicting prognosis and the immunotherapy response in pancreatic cancer. Co-author DOI 10.1007/s00018-024-05573-w↗
  3. Circular RNA LIPH promotes pancreatic cancer glycolysis and progression through sponge miR-769-3p and interaction with GOLM1. First author DOI 10.1002/ctm2.70003↗
  4. Plasma-derived exosomal long noncoding RNAs of pancreatic cancer patients as novel blood-based biomarkers of disease. Co-author DOI 10.1186/s12885-024-12755-z↗
  5. Exosomal lncRNA LINC01268 promotes pancreatic cancer progression via the miR-217-KIF2A-PI3K/AKT axis. Co-author DOI 10.1016/j.gendis.2022.12.018↗
  6. NamiRNA-enhancer network of miR-492 activates the NR2C1-TGF-β/Smad3 pathway to promote epithelial-mesenchymal transition of pancreatic cancer. First author DOI 10.1093/carcin/bgac102↗
  7. LncRNAs as epigenetic regulators of epithelial to mesenchymal transition in pancreatic cancer. Co-author DOI 10.1007/s12672-022-00522-0↗
  8. Identification of prognostic immune-related lncRNAs in pancreatic cancer. First author DOI 10.3389/fimmu.2022.1005695↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin Wang · 7 shared papers, 2022–2025 · strength 1.28
  2. Zhihui Bai · 4 shared papers, 2022–2025 · strength 0.79
  3. Shanshan Liu · 4 shared papers, 2022–2023 · strength 0.63
  4. Yan Ma · 3 shared papers, 2022–2023 · strength 0.46
  5. Li Xu · 2 shared papers, 2024–2025 · strength 0.41
  6. Jianqing Xu · 2 shared papers, 2023–2025 · strength 0.40
  7. Di Yang · 2 shared papers, 2022–2025 · strength 0.37
  8. Wenchuan Wu · 1 shared paper, 2025 · strength 0.22
  9. Jin Wang · 1 shared paper, 2024 · strength 0.21
  10. Yan Ma · 1 shared paper, 2024 · strength 0.19
  11. Xiaoyan Zhang · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.